Alprazolam intranasal - Questcor/Fabre Kramer

Drug Profile

Alprazolam intranasal - Questcor/Fabre Kramer

Alternative Names: Alprazolam intranasal - Questcor; Panistat

Latest Information Update: 13 Oct 2005

Price : $50

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Fabre-Kramer Pharmaceuticals; Questcor Pharmaceuticals
  • Class
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Panic disorder

Most Recent Events

  • 13 Oct 2005 Discontinued - Preclinical for Panic disorder in USA (Intranasal)
  • 05 Jul 2002 Fabre Kramer has licensed worldwide development and commercialisation rights from Questcor for intranasal alprazolam in the treatment of panic disorder
  • 29 Jun 2002 Preclinical trials in Panic disorder in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top